The US agency is reminding health-care professionals to return all Essure birth-control devices to its maker, Bayer AG, by 31 December. Although the company stopped selling Essure in the US in December 2018, professionals were allowed to continue implanting the problematic devices through the end of 2019. Meanwhile, the FDA updated its Sec. 522 postmarket surveillance study webpage for Essure.
The US Food and Drug Administration is reminding health-care professionals that they must return all Essure birth-control devices to its maker, Bayer AG, by 31 December.
Although the company stopped selling Essure in the US in December 2018, health-care professionals were allowed to continue implanting